Bausch Health Companies (BHC) Gains from Sales and Divestitures (2011)
Bausch Health Companies' (BHC) quarterly Gains from Sales and Divestitures came in at $672000.0 in Q4 2011, down 10.52% quarter-over-quarter from $751000.0 in Q3 2011.
Bausch Health Companies (BHC) Gains from Sales and Divestitures (2011) Analysis & Trends
Bausch Health Companies has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting $672000.0 for Q4 2011.
- Gains from Sales and Divestitures for Q4 2011 came in at $672000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2011 was $672000.0 (changed N/A YoY), and the FY2011 annual result was $672000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $672000.0 for Q4 2011 at Bausch Health Companies, down from $751000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q2 2011 to a low of $672000.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Bausch Health Companies | 1.93 Bn | 1.59 Bn | 2.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 672,000.00 |
| Dec 31, 2011 | 672,000.00 |
| Sep 30, 2011 | 751,000.00 |
| Sep 30, 2011 | 751,000.00 |
| Jun 30, 2011 | 1.25 Mn |
| Jun 30, 2011 | 1.25 Mn |